Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Not Yet Opened 03-17 16:00:00 EDT

2.27

+0.06

+2.71%

盘后2.27

+0.000.00%

19:48 EDT

High2.28	Low2.24	Vol26.35K
Open2.26	D1 Closing2.21	Amplitude1.81%
Mkt Cap30.60M	Tradable Cap19.61M	Total Shares13.48M
T/O59.65K	T/O Rate0.31%	Tradable Shares8.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":2.27,"timestamp":1773777600000,"preClose":2.21,"halted":0,"volume":26352,"hourTrading":{"tag":"盘后","latestPrice":2.27,"preClose":2.27,"latestTime":"19:48 EDT","volume":2705,"amount":6204.7693,"timestamp":1773791314049,"change":0,"changeRate":0,"amplitude":0.012467},"delay":0,"changeRate":0.02714932126696835,"floatShares":8637400,"shares":13481099,"eps":-10.103,"marketStatus":"Not Yet Opened","change":0.06,"latestTime":"03-17 16:00:00 EDT","open":2.26,"high":2.28,"low":2.24,"amount":59645.353967999996,"amplitude":0.0181,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.103,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773820800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":2.21,"preHourTrading":{"tag":"盘前","latestPrice":2.25,"preClose":2.21,"latestTime":"09:29 EDT","volume":112,"amount":246.31999839999997,"timestamp":1773754141046,"change":0.04,"changeRate":0.0181,"amplitude":0.049774},"postHourTrading":{"tag":"盘后","latestPrice":2.27,"preClose":2.27,"latestTime":"19:48 EDT","volume":2705,"amount":6204.7693,"timestamp":1773791314049,"change":0,"changeRate":0,"amplitude":0.012467},"volumeRatio":0.512169,"impliedVol":1.4125,"impliedVolPercentile":0.1765},"requestUrl":"/m/hq/s/TPST/wiki","defaultTab":"wiki","newsList":[{"id":"2618442799","title":"Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support","url":"https://stock-news.laohu8.com/highlight/detail?id=2618442799","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618442799?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:01","pubTimestamp":1773230494,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support               Tempest selected Cincinnati Children’s Applied Gene and Cell Therapy ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbS1mGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","TPST","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","BK4588","BK4112","SG9999014039.USD","IE00BKPKM429.USD","BK4585","NDAQ"],"gpt_icon":0},{"id":"2618494411","title":"Tempest Announces Partnership for Tpst-2003 in Preparation for Planned U.S. Registrational Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618494411","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618494411?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:00","pubTimestamp":1773230404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA72WWMX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2618291501","title":"Jakarta's Solution to Ease Burden on Bantargebang Landfill","url":"https://stock-news.laohu8.com/highlight/detail?id=2618291501","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618291501?lang=en_us&edition=fundamental","pubTime":"2026-03-11 10:58","pubTimestamp":1773197911,"startTime":"0","endTime":"0","summary":"TEMPO.CO,Jakarta-The Jakarta Provincial Government has outlined several solutions to ease the burden on the Bantargebang Integrated Waste Processing Site  in Bekasi, one of which is reducing waste at the source.Head of the Jakarta Environmental Agency, Asep Kuswanto, stated that the more waste that can be sorted and reduced, from households, offices, and residential areas, the less pressure the Bantargebang TPST, as the final processing site, will have to bear.\"Efforts to reduce waste at the source are an important part of Jakarta's long-term waste management strategy, as well as reducing the burden of landfills entering the final processing site each day,\" Asep said in a statement in Jakarta on Wednesday.","market":"fut","thumbnail":"https://statik.tempo.co/data/2026/03/09/id_1462772/1462772_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/03/09/id_1462772/1462772_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2091883/jakartas-solution-to-ease-burden-on-bantargebang-landfill","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2091883/jakartas-solution-to-ease-burden-on-bantargebang-landfill","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["RDF.AU","BK4139","TPST"],"gpt_icon":0},{"id":"2618048656","title":"Bantargebang Landfill Landslide Death Toll Rises to Five","url":"https://stock-news.laohu8.com/highlight/detail?id=2618048656","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618048656?lang=en_us&edition=fundamental","pubTime":"2026-03-10 07:35","pubTimestamp":1773099346,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-A joint search and rescue team found another victim in the landslide at the Bantargebang Integrated Waste Processing Site  in Bekasi City, Indonesia, on Monday, March 9, 2026. This discovery brings the death toll to five.Desiana Kartika Bahari, Head of the Jakarta SAR Office, stated that the team found the victim at around 12:05 p.m. Western Indonesian Time . \"At around 12:05 p.m. Western Indonesian Time , the team found another victim in a deceased condition,\" Desiana said on Monday.Desiana explained that officers had not yet been able to confirm the identity of the newly discovered victim. The SAR team then evacuated the body to the Kramat Jati National Police Hospital for identification. \"The body was immediately taken to the Kramat Jati National Police Hospital for identification,\" she said.","market":"fut","thumbnail":"https://statik.tempo.co/data/2026/03/09/id_1462771/1462771_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/03/09/id_1462771/1462771_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2091653/bantargebang-landfill-landslide-death-toll-rises-to-five","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2091653/bantargebang-landfill-landslide-death-toll-rises-to-five","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2618623036","title":"Bantargebang Landfill Tragedy Shows Waste Management Failure, Minister Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623036","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623036?lang=en_us&edition=fundamental","pubTime":"2026-03-09 13:00","pubTimestamp":1773032445,"startTime":"0","endTime":"0","summary":"The landslide of a 50-meter-high mountain of waste in Zone IV of the Bantargebang Landfill on Sunday  at 2:30 p.m. Western Indonesian Time , claiming four lives, is clear evidence of the systemic failure of waste management in Jakarta, which must no longer be tolerated.","market":"other","thumbnail":"https://statik.tempo.co/data/2026/03/09/id_1462721/1462721_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/03/09/id_1462721/1462721_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2091481/bantargebang-landfill-tragedy-shows-waste-management-failure-minister-says","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2091481/bantargebang-landfill-tragedy-shows-waste-management-failure-minister-says","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["LU2229751404.USD","LU1989772923.USD","LU1974910355.USD","LU2125910179.SGD","BK4139","LU2362541513.USD","LU2362541273.HKD","LU0057025933.USD","BK4120","BK4533","LU0289961442.SGD","LU2023250504.SGD","LU2355687059.USD","LU0289739343.SGD","LU1923621640.USD","LU2240825500.USD","LU2413666699.HKD","LU0347712357.USD","RDF.AU","LU2413666426.HKD","LU0175139822.USD","LU1623119135.USD","LU2238339852.HKD","LU2211814178.USD","LU0472753341.HKD","LU0069063385.USD","LU0158827781.USD","LU2028103732.USD","BK4588","LU0689626769.HKD","LU2089284900.SGD","LU1585245621.USD","LU2298064838.USD","LU2463526074.USD","LU1430594728.SGD","WM","LU2023250843.SGD","BK4566","LU2106854487.HKD","LU2125910336.SGD","LU2271345857.HKD","LU0289960550.SGD","LU0124676726.USD","TPST","LU2308191902.HKD","LU1939255532.USD","LU2023251221.USD","LU1712237335.SGD","LU2089283258.USD","LU1892829315.USD"],"gpt_icon":0},{"id":"2617069857","title":"3 People Killed in Bekasi's Bantargebang Landfill Landslide","url":"https://stock-news.laohu8.com/highlight/detail?id=2617069857","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617069857?lang=en_us&edition=fundamental","pubTime":"2026-03-08 22:36","pubTimestamp":1772980592,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-Three people were killed in a garbage landslide at the Bantargebang Integrated Waste Treatment Site  in Bekasi City on Sunday, March 8, 2026. The Head of the Jakarta SAR Office, Desiana Kartika Bahari, stated that the three victims included two food stall owners and a garbage truck driver.\"There are three fatalities. The victims were Enda Widayanti and Sumine, who were food stall owners, and a garbage truck driver named Dedi Sutrisno,\" she told reporters on Sunday.Desiana explained that the incident resulted in several garbage trucks being buried. However, authorities are still in the process of collecting data regarding the total number of potential victims.In a separate statement, the Head of the Bekasi City Environmental Agency, Kiswatiningsih, said they are still working to manage the waste landslide. Officials have not yet been able to determine the cause of the collapse. \"We have not received detailed information and are currently still handling the situation,\" ","market":"other","thumbnail":"https://statik.tempo.co/data/2023/10/30/id_1249852/1249852_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2023/10/30/id_1249852/1249852_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2091401/3-people-killed-in-bekasis-bantargebang-landfill-landslide","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2091401/3-people-killed-in-bekasis-bantargebang-landfill-landslide","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2614082668","title":"Tempest reports 100% complete response rate in interim REDEEM-1 trial of TPST-2003 CAR-T therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082668","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082668?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024355,"startTime":"0","endTime":"0","summary":"Tempest reports 100% complete response rate in interim REDEEM-1 trial of TPST-2003 CAR-T therapy               Tempest Therapeutics Inc. reported interim clinical data from the ongoing REDEEM-1 Phase ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL7hgbFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","NDAQ","BK4588","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","BK4139","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","TPST","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2614970082","title":"Tempest Therapeutics Inc - Favorable Safety Profile With No Grade 3 or Higher Crs","url":"https://stock-news.laohu8.com/highlight/detail?id=2614970082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614970082?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2614941082","title":"Tempest Therapeutics: Co Also Exploring Potential Development of Tpst-2003 to Include Patients With Lbcl, Other Related Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2614941082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614941082?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2614829460","title":"Tempest Therapeutics Inc - to Initiate U.S. Registrational Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614829460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614829460?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2614082961","title":"Tempest Therapeutics Inc - 100% Complete Response Rate Among All Six Efficacy Evaluable Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082961?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA22XVGC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2614082639","title":"Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082639?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":"100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244522/0/en/Tempest-Announces-Interim-Results-from-Ongoing-REDEEM-1-Trial-of-TPST-2003-Preparing-for-Potential-U-S-Registrational-Study-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","EMD","BK4195","TPST","PFS","BK4139","SLE","BK4161","LU2065731478.USD","CAR","IE00B66KJ199.SGD","IE0031619046.USD","BK4211","BK4077","BK4006","BK4187","BK4022","LU0963586101.USD","CRS","IE00B7SZL793.SGD","CR","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2610953407","title":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953407?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:04","pubTimestamp":1770818685,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z70I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMUS","NEM","FRSH","SCCO","MAT","AMZU","NET","RIO.UK","HOYY","KHC","HOOG","CDE","HOOD","GLTO","SHOP","THC","TPST","ROBN","BETA","R","MRNA","GILD","AVTR","CURB","AMZW","AMZN","HUM","PSN","USAW.SI","UPB","LYFT","BWA","CEG","HNGE","HL","HOOW","MCD","DTIL","AZYY","GFS","FCX","SHPU","AMZZ","QXO","BHP.AU","RIO.AU","AMZY","AU","AMZD"],"gpt_icon":0},{"id":"2610937358","title":"BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937358","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610937358?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:39","pubTimestamp":1770813594,"startTime":"0","endTime":"0","summary":"BUZZ-Tempest Therapeutics rises on partnerfunded plan for new cancer drugs** Shares of cancer drug developer Tempest Therapeutics TPST.O rise 2.07% to $2.47 premarket** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials** Co's TPST-2003, a dualtargeting CART for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support** Shares were down ~73% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z710Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2610093109","title":"Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies","url":"https://stock-news.laohu8.com/highlight/detail?id=2610093109","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610093109?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811169,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Outlines Future Plans to Advance Dual-Targeting CAR-T Programs, Expand In Vivo Pipeline, and Pursue Partner-Funded Development Strategies. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL87nMpG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4588","BK4112","NDAQ","IE00B3QW5Z07.USD","BK4139","SG9999014005.SGD","SG9999014021.USD","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","TPST","SG9999014039.USD"],"gpt_icon":0},{"id":"2610934355","title":"Tempest Therapeutics Inc - Plans to Progress Additional Dual Targeting Tpst-3003 CAR-T Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2610934355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610934355?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA32STZ2:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2610493103","title":"Tempest Therapeutics Inc - Expects Phase 2B Initiation for Tpst-2003 by 2026 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2610493103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610493103?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811140,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA32STZ2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2610088931","title":"Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2610088931","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610088931?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:59","pubTimestamp":1770811140,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA32STZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2609451511","title":"Tempest Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Matthew Angel","url":"https://stock-news.laohu8.com/highlight/detail?id=2609451511","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609451511?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:25","pubTimestamp":1770413124,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc. has filed an initial statement of beneficial ownership. The filing lists Matthew Angel, who serves as CEO, President, Director, and a 10% owner, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3wdMr1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempest Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Matthew Angel","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2609511634","title":"Tempest Therapeutics kündigt Privatplatzierung und unregistrierten Aktienverkauf an","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511634","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511634?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:13","pubTimestamp":1770412392,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc. hat eine Privatplatzierung und einen unregistrierten Aktienverkauf bekannt gegeben. Im Rahmen einer Transaktion am 3. Februar 2026 wurden rund 8,3 Millionen neue Stammaktien an Erigen ausgegeben. Nach Abschluss dieser Ausgabe hlt Erigen etwa 61% der ausstehenden Stammaktien von Tempest Therapeutics, whrend die bisherigen Aktionre rund 39% besitzen. Die Aktien wurden gem einer Ausnahmeregelung des US-Wertpapiergesetzes im Rahmen eines privaten Angebots ausgegeben und sind nicht registriert.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL8Hx1kD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":-0.0753},{"period":"1month","weight":-0.0636},{"period":"3month","weight":-0.2405},{"period":"6month","weight":-0.7693},{"period":"1year","weight":-0.7975},{"period":"ytd","weight":-0.23}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.032927},{"month":3,"riseRate":0.461538,"avgChangeRate":0.019848},{"month":4,"riseRate":0.25,"avgChangeRate":-0.140205},{"month":5,"riseRate":0.461538,"avgChangeRate":0.004949},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.113246},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.025247},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.054209},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.059229},{"month":10,"riseRate":0.461538,"avgChangeRate":0.94597},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction